Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12096099 | 1.00 | CA12 (0.50) | CA12CA9NR1H3TYRAKR1B1 | |
| SCHEMBL4287064 | 0.85 | TYR (0.62) | CA12CA9NR1H3TYRAKR1B1 | |
| SCHEMBL1491881 | 0.85 | CA12 (0.51) | CA12CA9NR1H3TYRAKR1B1 | |
| SCHEMBL4293129 | 0.85 | TYR (0.62) | CA12CA9NR1H3TYRAKR1B1 | |
| SCHEMBL4298856 | 0.85 | TYR (0.62) | CA12CA9NR1H3TYRAKR1B1 | |
| SCHEMBL15196950 | 0.85 | CA12 (0.54) | CA12CA9NR1H3TYRAKR1B1 | |
| SCHEMBL10103003 | 0.85 | CA12 (0.54) | CA12CA9NR1H3TYRAKR1B1 | |
| SCHEMBL1491947 | 0.85 | CA12 (0.51) | CA12CA9NR1H3TYRAKR1B1 | |
| SCHEMBL4289259 | 0.85 | TYR (0.62) | CA12CA9NR1H3TYRAKR1B1 | |
| SCHEMBL16021494 | 0.83 | CA12 (0.50) | CA12CA9NR1H3TYRAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313377-B1 | TREATMENT OF HELICOBACTER WITH ISOTHIOCYANATES | FAHEY JED W (US) | 2015-01-21 | — | — | EP | claimed |
| EP-2616442-A1 | INHIBITORS OF PI3K-DELTA AND METHODS OF THEIR USE AND MANUFACTURE | Exelixis, Inc. (US) | 2013-07-24 | — | — | EP | claimed |
| WO-2012037204-A1 | INHIBITORS OF PI3K-DELTA AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | claimed |
| US-20240115626-A1 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION OF ISOTHIOCYANATES | CHURCH & DWIGHT CO., INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-11801273-B2 | Compositions and methods to increase production of isothiocyanates | CHURCH & DWIGHT CO., INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20220193152-A1 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION OF ISOTHIOCYANATES | CHURCH & DWIGHT CO., INC. (US) | 2022-06-23 | — | — | US | disclosed |
| WO-2021255464-A1 | NUTRACEUTICAL COMPOSITION | HAHN NORMAN (GB) | 2021-12-23 | — | — | WO | disclosed |
| US-11026984-B2 | Use of isothiocyanate derivatives as modulators of peripheral and neuropathic pain | INDENA S.P.A. (IT) | 2021-06-08 | — | — | US | disclosed |
| EP-3280407-B1 | USE OF ISOTHIOCYANATE DERIVATIVES AS MODULATORS OF PERIPHERAL AND NEUROPATHIC PAIN | INDENA SPA (IT) | 2020-08-12 | — | — | EP | disclosed |
| US-20190046530-A1 | PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION, APOPTOSIS AND STRESS | KONSTANTOPOULOS KONSTANTINOS (US) | 2019-02-14 | — | — | US | disclosed |
| US-20180104293-A1 | USE OF ISOTHIOCYANATE DERIVATIVES AS MODULATORS OF PERIPHERAL AND NEUROPATHIC PAIN | INDENA S.P.A. (IT) | 2018-04-19 | — | — | US | disclosed |
| US-20100015085-A1 | PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION/INFECTION, APOPTOSIS AND STRESS | JOHNS HOPKINS UNIVERSITY | 2010-01-21 | — | — | US | disclosed |
| US-7402569-B2 | Treatment of Helicobacter with isothiocyanates | BRASSICA FOUNDATION FOR CHEMOPROTECTION RESEARCH, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-20080131578-A1 | FOOD OR DRINK PRODUCTS, SUPPLEMENTS OR ADDITIVES PRODUCED FROM HIGH GLUCORAPHANIN-CONTAINING BROCCOLI VARIETY 'HOPKINS' | Caudill Seed and Warehouse Company, Inc. | 2008-06-05 | — | — | US | disclosed |
| WO-2006065736-A2 | METHOD OF EXTRACTION OF ISOTHIOCYANATES INTO OIL FROM GLUCOSINOLSATE-CONTAINING PLANTS | JOHNS HOPKINS UNIVERSITY (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20040180843-A1 | Treatment of helicobacter with isothocyanates | BRASSICA FOUNDATION FOR CHEMOPROTECTION RESEARCH, INC. | 2004-09-16 | — | — | US | disclosed |
| US-6737441-B2 | PREVENTING OR TREATING PERSISTENT CHRONIC GASTRITIS, ULCERS AND/OR STOMACH CANCER | Fahey, Jed W. | 2004-05-18 | — | — | US | disclosed |
| EP-1313377-A2 | TREATMENT OF HELICOBACTER WITH ISOTHIOCYANATES | Fahey, Jed W. (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20020151505-A1 | Treatment of helicobacter with isothiocyanates | FAHEY, JED W. | 2002-10-17 | — | — | US | disclosed |
| WO-2002015722-A2 | TREATMENT OF HELICOBACTER WITH ISOTHIOCYANATES | FAHEY JED W (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190046530-A1 | PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION, APOPTOSIS AND STRESS | PTGS2, PTGES2, CCAR2 | CA12 4281/4885CA9 4327/4885NR1H3 496/4885 |
| US-20100015085-A1 | PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION/INFECTION, APOPTOSIS AND STRESS | PTGES2, PTGS2, PPARG | CA12 4133/4885CA9 4382/4885NR1H3 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.